Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.

Renal failure - 1 Nov 2020

Chen Jin, Li Yi, Li Guisen, Lei Pu

Abstract excerpt

Hepatitis C virus (HCV) infection is known to affect long-term patient survivals. Elbasvir/grazoprevir (EBR/GZR) has shown a high cure rate in hemodialysis patients with HCV infection. However, the combination is rarely used in peritoneal dialysis patients. Herein, we report a case of successful treatment with EBR/GZR in a peritoneal dialysis patient with HCV genotype 1 b infection. A 54-year-old woman on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Benzofurans
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Fatigue

Share to Peritoneal Dialysis

Share to Quinoxalines

Share to Sustained Virologic Response

Source

Open in PubMed Open full text

Identifiers

PMID: 32301365
DOI: 10.1080/0886022X.2020.1753073
PMCID: PMC7178844

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.PMID 32301365Read ↗

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.Semantic proximity Read ↗

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.Semantic proximity Read ↗

Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.Semantic proximity Read ↗

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.Semantic proximity Read ↗

Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.Semantic proximity Read ↗

Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.Semantic proximity Read ↗

Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].Semantic proximity Read ↗

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.Semantic proximity Read ↗

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.